Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
This is a placebo-controlled double-blind crossover comparative study of KW-6500 in
Parkinson's disease patients with motor response complications on levodopa therapy. The
efficacy of KW-6500 is evaluated using the change of UPDRS part III score at double blind
period after 12 weeks subcutaneous self-injections.
Phase:
Phase 3
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.